GOALS OF WORK: The goal of this study was to develop a new, objective prognostic score (OPS) for terminally ill cancer patients based on an integrated model that includes novel objective prognostic factors. MATERIALS AND METHODS: A multicenter study of 209 terminally ill cancer patients from six training hospitals in Korea were prospectively followed until death. The Cox proportional hazard model was used to adjust for the influence of clinical and laboratory variables on survival time. The OPS was calculated from the sum of partial scores obtained from seven significant predictors determined by the final model. The partial score was based on the hazard ratio of each predictor. The accuracy of the OPS was evaluated. MAIN RESULTS: The overall median survival was 26 days. On the multivariate analysis, reduced oral intake, resting dyspnea, low performance status, leukocytosis, elevated bilirubin, elevated creatinine, and elevated lactate dehydrogenase (LDH) were identified as poor prognostic factors. The range of OPS was from 0.0 to 7.0. For the above cutoff point of 3.0, the 3-week prediction sensitivity was 74.7%, the specificity was 76.5%, and the overall accuracy was 75.5%. CONCLUSIONS: We developed the new OPS, without clinician's survival estimates but including a new prognostic factor (LDH). This new instrument demonstrated accurate prediction of the 3-week survival. The OPS had acceptable accuracy in this study population (training set). Further validation is required on an independent population (testing set).
GOALS OF WORK: The goal of this study was to develop a new, objective prognostic score (OPS) for terminally ill cancerpatients based on an integrated model that includes novel objective prognostic factors. MATERIALS AND METHODS: A multicenter study of 209 terminally ill cancerpatients from six training hospitals in Korea were prospectively followed until death. The Cox proportional hazard model was used to adjust for the influence of clinical and laboratory variables on survival time. The OPS was calculated from the sum of partial scores obtained from seven significant predictors determined by the final model. The partial score was based on the hazard ratio of each predictor. The accuracy of the OPS was evaluated. MAIN RESULTS: The overall median survival was 26 days. On the multivariate analysis, reduced oral intake, resting dyspnea, low performance status, leukocytosis, elevated bilirubin, elevated creatinine, and elevated lactate dehydrogenase (LDH) were identified as poor prognostic factors. The range of OPS was from 0.0 to 7.0. For the above cutoff point of 3.0, the 3-week prediction sensitivity was 74.7%, the specificity was 76.5%, and the overall accuracy was 75.5%. CONCLUSIONS: We developed the new OPS, without clinician's survival estimates but including a new prognostic factor (LDH). This new instrument demonstrated accurate prediction of the 3-week survival. The OPS had acceptable accuracy in this study population (training set). Further validation is required on an independent population (testing set).
Authors: Francis Lau; Denise Cloutier-Fisher; Craig Kuziemsky; Fraser Black; Michael Downing; Elizabeth Borycki; Francis Ho Journal: J Palliat Care Date: 2007 Impact factor: 2.250
Authors: M Pirovano; M Maltoni; O Nanni; M Marinari; M Indelli; G Zaninetta; V Petrella; S Barni; E Zecca; E Scarpi; R Labianca; D Amadori; G Luporini Journal: J Pain Symptom Manage Date: 1999-04 Impact factor: 3.612
Authors: William G Hawkins; Ronald P DeMatteo; William R Jarnagin; Leah Ben-Porat; Leslie H Blumgart; Yuman Fong Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: Monica S Krishnan; Zachary Epstein-Peterson; Yu-Hui Chen; Yolanda D Tseng; Alexi A Wright; Jennifer S Temel; Paul Catalano; Tracy A Balboni Journal: Cancer Date: 2013-10-02 Impact factor: 6.860
Authors: Dimitris Bertsimas; Jack Dunn; Colin Pawlowski; John Silberholz; Alexander Weinstein; Ying Daisy Zhuo; Eddy Chen; Aymen A Elfiky Journal: JCO Clin Cancer Inform Date: 2018-12
Authors: Maryam Dosani; Scott Tyldesley; Brendan Bakos; Jeremy Hamm; Tim Kong; Sarah Lucas; Jordan Wong; Mitchell Liu; Sarah Hamilton Journal: Support Care Cancer Date: 2018-02-01 Impact factor: 3.603